This is a snippet of the transcript.Contact Salesto get full access.
I advised them to proceed because with some single-use support, we aimed to develop the product in Long Island, U.S., close to the American pharmaceutical industry, which wanted local development. I suggested buying them for €100 million. Buy, buy, buy. The same decision was made again. About a year and a half ago, the value of single-use support reached €1 billion or dollars and was acquired by Danaher. This contributed to the strong decline of Sartorius. I was frustrated with René Fáber because he ignored my recommendations and trusted people who eventually were let go a year later. It was a clear mistake not to make the right investment. They invested in other companies, and I believe those investments were excessively high. To put it briefly, Sartorius lost significant market shares, especially in the last part in FMT, because single-use support not only developed the frozen transport system, which is now state-of-the-art, but also the freeze and thaw system and the filling system.
This is a snippet of the transcript.Contact Salesto get full access.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.